Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Cogint, Inc. (COGT) is “One to Watch”

Distilling complexity into actionable intelligence is the core focus for recently rebranded data analytics outfit Cogint, Inc. (NASDAQ: COGT). Cogint rang the NASDAQ bell (http://dtn.fm/OTm74) only a handful of days after transitioning shares over to the exchange, amid a big push by the company to secure and expand an increasingly dominant footprint in massive scale, […]

Professional Diversity Network, Inc. (IPDN) Closes Stock Sale Transaction with Cosmic Forward Limited

In a recent news release by Professional Diversity Network, Inc. (NASDAQ: IPDN), it was announced that Cosmic Forward Limited (“CFL”), a Seychelles-based private company, now owns 51% of the Internet software and services company, which specializes in providing career networking for women and diverse professionals. IPDN recently completed the sale of 1,777,417 shares of its […]

GainClients, Inc. (GCLT) is “One to Watch”

GainClients, Inc. (OTC: GCLT) is a software service company focused primarily on the development of marketing services for real estate professionals and valuable home search and area information tools for consumers. The company’s innovations expound the popularity of online networks by helping real estate professionals better serve their clients through the sharing of accurate real […]

Ampio Pharmaceuticals, Inc. (AMPE) Targeting Common Inflammatory Conditions with Two Late-Stage Product Candidates

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) is a development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options. The company’s development pipeline currently features two product candidates advancing through late-stage clinical trials in the United States, including Ampion™ for […]

CytoSorbents Corp. (CTSO) is “One to Watch”

November has been a promising month for CytoSorbents Corp. (NASDAQ: CTSO), a critical care immunotherapy company. The New Jersey-based company, specializing in blood purification to control deadly inflammation in critically ill and cardiac surgery patients, reported its financial results for the third quarter ended September 30, 2016. CTSO reported that product sales for the third […]

Inovio Pharmaceuticals, Inc. (INO) opens New Front Line in War against Cancer & Infectious Diseases with DNA Vaccines

Over 2,000 years ago, Plato, in his immortal Socratic dialogue, had the great philosopher express his astonishment at the new diseases plaguing Athenian society and their bizarre and horrible names. Our position today is very similar. Strange, horrible afflictions with bizarre, frightening names like cancer, Ebola and Zika, unknown or unrecognized until modern times, threaten […]

Aegis Capital Supports ‘Buy’ Rating, Higher Stock Price Target for Progenics (PGNX) Following Strong Q3 Results

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), a company focused on the development of innovative treatments and therapies for cancer, in particular prostate cancer, recently released its financial results for the third quarter of 2016, reporting higher revenue and net income compared to the third quarter of 2015. The growth can be primarily attributed to the FDA […]

Nektar Therapeutics (NKTR) is “One to Watch”

Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company in the business of developing new medicines for people living with life changing conditions, now helps more than nine million patients worldwide. Nektar also offers a proprietary pipeline made up of drug candidates for oncology, pain, anti-infectives, and immunology. The company has 12 approved products, including Movantik, Adynovate, […]

 

From Our Blog

D-Wave Quantum Inc. (NYSE: QBTS) Announces First-Ever Qubits Japan 2025 Quantum Computing User Conference

September 16, 2025

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or “The Company”), a leader in quantum computing systems, software, and services, recently announced that it is hosting its first-ever Qubits Japan 2025 quantum computing user conference in Tokyo on September 17 to support growing interest and adoption of annealing quantum computing technology across the Asia Pacific (“APAC”) region.  […]

Rotate your device 90° to view site.